European equities traded in the US as American depositary receipts were slightly lower late Wednesday morning, declining 0.14% to 1,346.88 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical firm DBV Technologies (DBVT), which rose 3.3% and 2.1%, respectively. They were followed by software firm SAP (SAP) and internet advertising company Criteo (CRTO), which were up 1.8% and 1.6%, respectively.
The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and pharmaceutical company Ascendis Pharma (ASND), which fell 6.4% and 5.7% respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company Genfit (GNFT), which lost 4% and 3.7% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Adaptimmune Therapeutics (ADAP), which increased 3.3% and 0.9% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and hospitality company InterContinental Hotels Group (IHG), which were up 0.8% and 0.7% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Akari Therapeutics (AKTX), which dropped 6.4% and 3.5% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and utilities company National Grid (NGG), which were down 2.3% and 2.1% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.